Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial)

Delphine Hoegy, Nathalie Bleyzac, Alexandra Gauthier-Vasserot, Giovanna Cannas, Angélique Denis, Arnaud Hot, Yves Bertrand, Pauline Occelli, Sandrine Touzet, Claude Dussart, Audrey Janoly-Dumenil, DREPADO study group, C Pivot, C Pondarre, F Galactéros, E Fois, M De Montalembert, J B Arlet, G Elana, K Michaux, C Guitton, C Chantalat, S Eyssette-Guerreau, L Blum, Delphine Hoegy, Nathalie Bleyzac, Alexandra Gauthier-Vasserot, Giovanna Cannas, Angélique Denis, Arnaud Hot, Yves Bertrand, Pauline Occelli, Sandrine Touzet, Claude Dussart, Audrey Janoly-Dumenil, DREPADO study group, C Pivot, C Pondarre, F Galactéros, E Fois, M De Montalembert, J B Arlet, G Elana, K Michaux, C Guitton, C Chantalat, S Eyssette-Guerreau, L Blum

Abstract

Background: Thanks to advancements in medical care, a majority of patients with sickle cell disease (SCD) worldwide live beyond 18 years of age, and therefore, patients initially followed in paediatric departments are then transferred to adult departments. This paediatric-adult care transition is a period with an increased risk of discontinuity of care and subsequent morbidity and mortality. During this period, the patient will have to manage new interlocutors and places of care, and personal issues related to the period of adolescence. To take into consideration all these aspects, an interesting approach is to use the whole system approach to the patient, as presented in the biopsychosocial approach. The aim of this trial is to evaluate the impact of the proposed biopsychosocial paediatric-adult transition programme.

Methods: The DREPADO study is a multicentre randomised control trial comparing a control group (Arm A) to an interventional group with a paediatric-adult transition programme based on a biopsychosocial approach (Arm B). To be included, patients should have the SS, SC, or Sβ form of sickle cell disease and be aged between 16 and 17 years. The randomisation in a 1:1 ratio assigns to Arm A or B. The primary outcome is the number of hospital admissions and emergencies for complications in the index hospital, in the 2 years after the first consultation in the adult department of care. Secondary outcomes consider the quality of life, but also include coping skills such as sense of self-efficacy and disease knowledge. To provide patient and parent knowledge and coping skills, the transition programme is composed of three axes: educational, psychological, and social, conducted individually and in groups.

Discussion: By providing self-care knowledge and coping skills related to SCD and therapeutics, helping empower patientsin relation to pain management and emotions, and facilitating the relationship to oneself, others, and care in Arm B of the DREPADO study, we believe that the morbidity and mortality of patients with SCD may be reduced after the proposed paediatric-adult transition programme.

Trial registration: ClinicalTrials.gov, ID: NCT03786549; registered on 17 December 2018; https://clinicaltrials.gov/.

Keywords: Paediatric-adult care transition; Sickle cell disease.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
SPIRIT flow diagram of the DREPADO trial
Fig. 2
Fig. 2
Detailed study scheme of the DREPADO trial

References

    1. de Montalembert M, Guitton C. French Reference Centre for Sickle Cell Disease. Transition from paediatric to adult care for patients with sickle cell disease. Br J Haematol. 2014;164:630–635. doi: 10.1111/bjh.12700.
    1. Berens John C., Jan Sophia, Szalda Dava, Hanna Christina M. Young Adults With Chronic Illness: How Can We Improve Transitions to Adult Care? Pediatrics. 2017;139(5):e20170410. doi: 10.1542/peds.2017-0410.
    1. Treadwell M, Telfair J, Gibson RW, Johnson S, Osunkwo I. Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol. 2011;86:116–120. doi: 10.1002/ajh.21880.
    1. Sabaté E. Adherence to long-term therapies: evidence for action: World Health Organization; 2003. . Accessed 20 June 2018
    1. Crosby LE, Modi AC, Lemanek KL, Guilfoyle SM, Kalinyak KA, Mitchell MJ. Perceived barriers to clinic appointments for adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2009;31:571–576. doi: 10.1097/MPH.0b013e3181acd889.
    1. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115:3447–3452. doi: 10.1182/blood-2009-07-233700.
    1. Brousseau David C. Acute Care Utilization and Rehospitalizations for Sickle Cell Disease. JAMA. 2010;303(13):1288. doi: 10.1001/jama.2010.378.
    1. Morsa M, Lombrail P, Boudailliez B, Godot C, Jeantils V, Gagnayre R. A qualitative study on the educational needs of young people with chronic conditions transitioning from pediatric to adult care. Patient Prefer Adherence. 2018;12:2649–2660. doi: 10.2147/PPA.S184991.
    1. Kinney TR, Ware RE. The adolescent with sickle cell anemia. Hematol Oncol Clin North Am. 1996;10:1255–1264. doi: 10.1016/S0889-8588(05)70398-1.
    1. Hoegy D, Guilloux R, Bleyzac N, Gauthier-Vasserot A, Cannas G, Bertrand Y, Hot A, Dussart C, Janoly-Dumenil A. Sickle cell disease perceptions of caregivers, adolescent and adult patients: barriers and facilitators to medical care adherence. J Pain Symptom Manag. submitted.
    1. Crosby LE, Quinn CT, Kalinyak KA. A biopsychosocial model for the management of patients with sickle-cell disease transitioning to adult medical care. Adv Ther. 2015;32:293–305. doi: 10.1007/s12325-015-0197-1.
    1. Mulchan SS, Valenzuela JM, Crosby LE, Diaz Pow Sang C. Applicability of the SMART model of transition readiness for sickle-cell disease. J Pediatr Psychol. 2016;41:543–554. doi: 10.1093/jpepsy/jsv120.
    1. Campbell F, Biggs K, Aldiss SK, et al. Transition of care for adolescents from paediatric services to adult health services. Cochrane Database Syst Rev. 2016;4:CD009794. doi: 10.1002/14651858.CD009794.pub2.
    1. Crosby LE, Joffe NE, Peugh J, Ware RE, Britto MT. Pilot of the chronic disease self-management program for adolescents and young adults with sickle cell disease. J Adolesc Health. 2017;60:120–123. doi: 10.1016/j.jadohealth.2016.08.022.
    1. Kaslow N, Collins HM, Rashid FL, Eckman JE. The efficacy of a pilot family psychoeducational intervention for pediatric sickle cell disease (SCD) Fam Syst Health. 2000;18:381–404. doi: 10.1037/h0091863.
    1. Smith GM, Lewis VR, Whitworth E, Gold DT, Thornburg CD. Growing up with sickle cell disease: a pilot study of a transition program for adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2011;33:379–382. doi: 10.1097/MPH.0b013e318211bb2e.
    1. Dima Alexandra L, Van Ganse E, Laforest L, Texier N, de Bruin M, ASTRO-LAB Group Measuring medication adherence in asthma: development of a novel self-report tool. Psychol Health. 2017;32(10):1288–1307. doi: 10.1080/08870446.2017.1290248.
    1. Misdrahi D, Verdoux H, Llorca PM, Baylé FJ. Therapeutic adherence and schizophrenia: the interest of the validation of the French translation of Medication Adherence Rating Scale (MARS) Encephale. 2004;30:409–410.
    1. Rouquette A, Nadot T, Labitrie P, Van den Broucke S, Mancini J, Rigal L, Ringa V. Validity and measurement invariance across sex, age, and education level of the French short versions of the European Health Literacy Survey Questionnaire. PLoS One. 2018;13(12):e0208091. doi: 10.1371/journal.pone.0208091.
    1. Edwards R, Telfair J, Cecil H, Lenoci J. Reliability and validity of a self-efficacy instrument specific to sickle cell disease. Behav Res Ther. 2000;38:951–963. doi: 10.1016/S0005-7967(99)00140-0.
    1. Fugier Pascal. L'intervention socio-éducative au domicile. VST - Vie sociale et traitements. 2014;121(1):101. doi: 10.3917/vst.121.0101.
    1. Charoud M. [L’engagement des associations de patients atteints de maladies chroniques: Du « savoir patient » aux strategies de communication]. Polit Commun 2017 ; 9, 37–62.
    1. Morrison KM, Ball GDC, Ho J, Mackie P, Buchholz A, Chanoine J-P, et al. The CANadian Pediatric Weight management Registry (CANPWR): lessons learned from developing and initiating a national, multicentre study embedded in pediatric clinical practice. BMC Pediatr. 2018;18:237. doi: 10.1186/s12887-018-1208-6.
    1. Lainé A, 2009. [Construction d’un stigmate sanitaire: la drépanocytose entre situations locales et globales.] hal-00436022. . Accessed 20 June 2018.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe